Subsequent RCTs and open-label trials in AS patients, however, found that the incidence of new-onset IBD was comparable to placebo in patients receiving TNF inhibitors, namely, infliximab, etanercept, and adalimumab [41]. The gene discussed is TNF; the disease is inflammatory bowel disease.